Category: Finance
Pfizer's shares rose 4.1% after the company exceeded Q2 earnings expectations and raised its full-year outlook, driven by its oncology portfolio and cost realignment efforts. Adjusted earnings were $0.60 per share on $13.28B revenue, marking the first year-over-year revenue growth since Q4 2022. Despite declines in COVID-19 product revenues, overall operational revenue grew 3%. The company raised its 2024 revenue guidance by $1B, anticipating 9-11% growth excluding COVID products.
Keywords: Pfizer, earnings report, revenue growth
Update At: 7/30/2024